Related references
Note: Only part of the references are listed.Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism
Francois Briand et al.
DIABETES (2016)
Pathophysiology of lipid droplet proteins in liver diseases
Rotonya M. Carr et al.
EXPERIMENTAL CELL RESEARCH (2016)
The Mechanisms and Therapeutic Potential of SGLT2 Inhibitors in Diabetes Mellitus
Volker Vallon
ANNUAL REVIEW OF MEDICINE, VOL 66 (2015)
Effect of a new PPAR-gamma agonist, lobeglitazone, on neointimal formation after balloon injury in rats and the development of atherosclerosis
Soo Lim et al.
ATHEROSCLEROSIS (2015)
Mechanistic link between nonalcoholic fatty liver disease and cardiometabolic disorders
Soo Lim et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Effect of Repetitive Glucose Spike and Hypoglycaemia on Atherosclerosis and Death Rate in Apo E-Deficient Mice
Kenichi Nakajima et al.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (2015)
Adipokines, diabetes and atherosclerosis: an inflammatory association
Leandro C. Freitas Lima et al.
FRONTIERS IN PHYSIOLOGY (2015)
Metformin Inhibits Monocyte-to-Macrophage Differentiation via AMPK-Mediated Inhibition of STAT3 Activation: Potential Role in Atherosclerosis
Sathish Babu Vasamsetti et al.
DIABETES (2015)
Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice
Michishige Terasaki et al.
PLOS ONE (2015)
Identification of Cardiometabolic Risk: Visceral Adiposity Index Versus Triglyceride/HDL Cholesterol Ratio
Martin R. Salazar et al.
AMERICAN JOURNAL OF MEDICINE (2014)
Modulation of adiponectin as a potential therapeutic strategy
Soo Lim et al.
ATHEROSCLEROSIS (2014)
C-reactive protein promotes atherosclerosis by increasing LDL transcytosis across endothelial cells
Fang Bian et al.
BRITISH JOURNAL OF PHARMACOLOGY (2014)
Impact of MCP-1 in Atherosclerosis
Juntang Lin et al.
CURRENT PHARMACEUTICAL DESIGN (2014)
Sodium- Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open- Label Proof- ofConcept Trial
Bruce A. Perkins et al.
DIABETES CARE (2014)
Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis
S. Goring et al.
DIABETES OBESITY & METABOLISM (2014)
Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis
A. Liakos et al.
DIABETES OBESITY & METABOLISM (2014)
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ele Ferrannini et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Hepatic trans-Golgi action coordinated by the GTPase ARFRP1 is crucial for lipoprotein lipidation and assembly
Deike Hesse et al.
JOURNAL OF LIPID RESEARCH (2014)
Cardiovascular and hemodynamic effects of glucagon-like peptide-1
Adam G. Goodwill et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2014)
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial
Martin Ridderstrale et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Sodium-Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes A Systematic Review and Meta-analysis
Despoina Vasilakou et al.
ANNALS OF INTERNAL MEDICINE (2013)
A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes
E. Ferrannini et al.
DIABETES OBESITY & METABOLISM (2013)
Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
K. Stenlof et al.
DIABETES OBESITY & METABOLISM (2013)
Effects of Combining Linagliptin Treatment with BI-38335, A Novel SGLT2 Inhibitor, on Pancreatic Islet Function and Inflammation in db/db Mice
L. Chen et al.
CURRENT MOLECULAR MEDICINE (2012)
Stress Augments Insulin Resistance and Prothrombotic State
Yasuhiro Uchida et al.
DIABETES (2012)
Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
Jan Bolinder et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity
K. Yamamoto et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
Effect of S-adenosylmethionine on neointimal formation after balloon injury in obese diabetic rats
Soo Lim et al.
CARDIOVASCULAR RESEARCH (2011)
Reduced Adipose Tissue Inflammation Represents an Intermediate Cardiometabolic Phenotype in Obesity
Melissa G. Farb et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2011)
Modulation of lipid droplet size and lipid droplet proteins by trans-10,cis-12 conjugated linoleic acid parallels improvements in hepatic steatosis in obese, insulin-resistant rats
Danielle M. Stringer et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2010)
Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure
Que Liu et al.
CARDIOVASCULAR DIABETOLOGY (2010)
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
Clifford J. Bailey et al.
LANCET (2010)
Pioglitazone vs glimepiride: Differential effects on vascular endothelial function in patients with type 2 diabetes
Katerina Papathanassiou et al.
ATHEROSCLEROSIS (2009)
Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus
B. Komoroski et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
James F. List et al.
DIABETES CARE (2009)
Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug
Iskandar Idris et al.
DIABETES OBESITY & METABOLISM (2009)
Adipose macrophage infiltration is associated with insulin resistance and vascular endothelial dysfunction in obese subjects
Caroline M. Apovian et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2008)
Abnormal liver function test predicts type 2 diabetes
Nam H. Cho et al.
DIABETES CARE (2007)
Diabetic atherosclerosis mouse models
Kenneth K. Wu et al.
ATHEROSCLEROSIS (2007)
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes - A randomized trial
Theodore Mazzone et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Monocyte and macrophage heterogeneity
S Gordon et al.
NATURE REVIEWS IMMUNOLOGY (2005)
Phlorizin: a review
JRL Ehrenkranz et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2005)
Adiponectin expression from human adipose tissue -: Relation to obesity, insulin resistance, and tumor necrosis factor-α expression
PA Kern et al.
DIABETES (2003)